Baker & McKenzie LLP
08/28/2025 | Press release | Distributed by Public on 08/28/2025 00:44
Baker McKenzie Advises the Shareholders of Swiss Cardio Technologies AG on their Sale to Abacus Medicine Group
Baker McKenzie has advised the shareholders of Swiss Cardio Technologies AG ("Swiss Cardio Technologies"), a medical company specializing in cardiovascular surgery solutions, on the sale of all their shares to Abacus Medicine Group. Founded in Denmark in 2004, Abacus Medicine Group is a leading pharmaceutical company focused on the parallel import of medicines to enhance access and affordability.
Swiss Cardio Technologies AG, established by renowned cardiovascular surgeons from the University of Berne, developed Cardioplexol®, an innovative cardioplegia solution used to safely arrest the heart during complex surgical procedures such as bypass operations and aortic repairs. The transaction is expected to accelerate international commercialization and expansion of Cardioplexol®, leveraging Abacus' extensive global network alongside Swiss Cardio Technologies' relationships in cardiothoracic surgery.
Baker McKenzie advised the shareholders of Swiss Cardio Technologies on all legal aspects of the transaction.
Zurich-based partners Alexander Fischer (M&A) and Julia Schieber (M&A, Healthcare & Sciences) led the team, which consisted of the following: Matthias Trautmann (partner, M&A), Hesam Mirzai (associate, M&A) as well as trainee lawyers Elena Mani and Grégory Sarbach.
Swiss Cardio Technologies AG, established by renowned cardiovascular surgeons from the University of Berne, developed Cardioplexol®, an innovative cardioplegia solution used to safely arrest the heart during complex surgical procedures such as bypass operations and aortic repairs. The transaction is expected to accelerate international commercialization and expansion of Cardioplexol®, leveraging Abacus' extensive global network alongside Swiss Cardio Technologies' relationships in cardiothoracic surgery.
Baker McKenzie advised the shareholders of Swiss Cardio Technologies on all legal aspects of the transaction.
Zurich-based partners Alexander Fischer (M&A) and Julia Schieber (M&A, Healthcare & Sciences) led the team, which consisted of the following: Matthias Trautmann (partner, M&A), Hesam Mirzai (associate, M&A) as well as trainee lawyers Elena Mani and Grégory Sarbach.
Baker & McKenzie LLP published this content on August 28, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 28, 2025 at 06:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]